PRIORITY SERVICES

The Brazilian Registry of Clinical Trials (ReBEC) presents the new fast tracks for clinical research and observational studies on INDIGENOUS PEOPLE AND TRADITIONAL COMMUNITIES and on NEGLECTED TROPICAL DISEASES (NTDs). Fast-track can reduce the normal approval period for clinical trials to less than 48 hours, if the documentation, information and any mandatory changes requested are provided by the registrant.

The already existing fast-tracks and the attendance to other studies will not be interrupted. Priority care is granted with a view to accelerating clinical research in epidemiological emergency situations and/or studies with the potential to reduce socioeconomic inequalities, keeping the perspective aligned with the forefront of ethics and transparency, diplomacy in health, scientific collaboration and diversity and specificities of recruitment and health care.

FAST-TRACKS IN OPERATION:

I - Indigenous Peoples, Traditional Communities, Human Migration and Refugee Movements – clinical research and observational studies dedicated to or preferably addressing traditional communities (quilombola, caiçara, faxinalense, among others), Indigenous peoples (within or outside legally demarcated territories), and refugee groups, taking into account the specificities established by regulation, on a case-by-case basis.

II - Neglected Tropical Diseases – Leprosy, Tuberculosis, Leishmaniasis, Schistosomiasis, Scabies, Chagas disease, Intestinal parasitoses, Viral hepatitis, Trachoma, Onchocerciasis, Human rabies transmitted by dogs.

III - National and International Public Health Emergencies – Mpox, Covid-19.

IV - Arboviruses – Zika, Dengue, Chikungunya, Malaria, Yellow fever.

V - WHO Prioritized Pathogens for Latin America – Studies dealing with World Health Organization prioritized pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Lassa fever, Cholera, Black Death (Plague), Bacillary dysentery or Shigellosis, Salmonella, Pneumonia, Urinary tract infection, MERS-CoV, SARS, Ebola virus (EVE), Marburg virus (MVE), Ebola virus (EVE) Sudan subtype, Hantavirus pulmonary syndrome (HPS), Hemorrhagic fever with renal syndrome (HFRS), Crimean-Congo hemorrhagic fever, Influenza A H1, Influenza A H2, Influenza A H3, Avian influenza (Influenza A H5N1), Avian influenza (Influenza A H6), Avian influenza H7 (Avian influenza H7), Avian influenza H10 or Avian influenza H10, Nipah disease, Viral hemorrhagic disease, Poliomyelitis, Hand-foot-and-mouth disease, Herpangina, Viral meningitis, Smallpox, Mpox, Human Immunodeficiency Virus (HIV), Venezuelan equine encephalitis (VEE).

VI - WHO Prioritized Prototype Pathogens for Latin America – Studies dealing with World Health Organization prioritized prototype pathogens for Latin America, as listed in the document "PATHOGENS PRIORITIZATION - A SCIENTIFIC FRAMEWORK FOR EPIDEMIC AND PANDEMIC RESEARCH PREPAREDNESS" (Health Emergencies Programme, 2024) – Recombinant mastadenovirus, Mastadenovirus blackbeardi serotype 14, Mammarenavirus juninense, Mammarenavirus lujoense, Mamastrovirus virginiaense, Orthobornavirus bornaense, Orthoflavivirus encephalitidis, Orthoflavivirus nilense, Orthohepadnavirus hominoidae genotype C, Paslahepevirus balayani genotype 3, Protoparvovirus carnivoran, Orthobunyavirus oropoucheense, Phlebovirus riftense, Orthopicobirnavirus hominis, Enterovirus alphacoxsackie 71, Enterovirus deconjuncti 68, Metapneumovirus hominis, Orthopoxvirus vaccinia, Genus Vesiculovirus, Genus Rotavirus, Orthoreovirus mammalis.

VII - Studies on the impacts of climate change, the effects of scientific denialism, and health misinformation -The physical, mental, and social consequences of environmental and climate changes on human populations; The impact of extreme weather events and environmental degradation on infectious, chronic, or emerging diseases; The influence of denialist narratives and misinformation in Health on adherence to preventive measures, vaccination, treatments, and risk behaviors, as well as the physical and mental outcomes for human beings and populations.

INSTRUCTIONS:

We recommend reading the Registrant Handbook. Material available at LINK.

1. Register or log in and normally fill out the forms in Portuguese and English. For English, in case of difficulty, use the Google Translate tool (or another free translation tool).
2. Attach the mandatory ethics committee documentation and submit the form.
3. Register the service number on your Whatsapp. Send a message with your name and login. IT IS NOT NECESSARY NOR RECOMMENDED TO SEND YOUR PASSWORD.
4. A reviewer will respond to you. Choose the service modality: chat, audio recordings or voice call by appointment.
5. Your form will be proofread in both languages. Follow the remaining guidelines to finalize the approval.

CONTACTS:

Support is online, via chat, dedicated telephone line (see phone number below) and WhatsApp, from 9 am to 5 pm (Brasília time).

Administrative, priority and/or urgent matters outside office hours: plantao.rebec@gmail.com
Line 1: +55 21 97203-4750

ABOUT REBEC:

The Brazilian Registry of Clinical Trials (ReBEC) is a free access virtual platform for recording experimental and non-experimental studies carried out on human beings and conducted in Brazilian territory, by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (OPAS) and the Oswaldo Cruz Foundation (FIOCRUZ). ReBEC's Executive Committee is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA).

11/21/2025  |  Drug Target Review  

https://www.drugtargetreview.com/article/190616/ai-and-policy-reform-set-to-reshape-uk-drug-development/ 

BCG’s Chris Meier outlines how advances in AI and new UK policies could accelerate drug development, streamline clinical trials and strengthen the country’s life sciences sector.

Every year, pharmaceutical companies invest billions in research and development, yet only a small fraction of newly discovered medicines reach patients. Lengthy clinical timelines, complex regulations and fragmented data infrastructures continue to delay progress. The UK Government’s recent plan to reduce clinical trial set-up times from nine months to ten weeks is an attempt to remove one of the most persistent bottlenecks in the drug development process.

For Chris Meier, Managing Director and Partner at Boston Consulting Group (BCG) based in London, this initiative arrives at a critical time. Leading BCG’s global work on AI, data and analytics in biopharma, Meier advises pharmaceutical companies on how digital innovation can shorten timelines, improve efficiency and enable new modes of drug discovery.

“The UK Government’s plan to cut clinical trial set-up times is a welcome move. The UK has many world-class hospitals where pharmaceutical companies want to run trials, and shortening start-up timelines will make the UK even more competitive and attractive globally.”

Streamlining trials for faster access

Clinical trials remain one of the most resource-intensive stages of drug development. Administrative processes alone can consume months, slowing access to innovative treatments. Meier believes that faster start-up times will make a measurable difference both commercially and scientifically.

11/25/2025 | Correio Brasiliense (opinion)

https://www.correiobraziliense.com.br/opiniao/2025/11/7296806-anvisa-habilita-avanco-em-pesquisas-com-cannabis.html#google_vignette 

The authorization granted to Embrapa does not, in itself, equate to the liberalization of the market. It enables essential elements for the production of safe and economically viable pharmaceutical inputs.

Anvisa's decision, published this Wednesday, to grant Embrapa's request and authorize the institution's cannabis cultivation research inaugurates a new phase in the public debate about the plant in Brazil. The permission, clearly limited to the scientific field and subject to strict controls, represents both a technical advance and a test of regulatory governance on a topic that coexists with social stigmas and economic interests.

In truth, from a legal standpoint, Brazil has not yet adopted a comprehensive regime for cultivation for medicinal use—authorized production has been granted on a case-by-case basis, under criteria from Anvisa (the Brazilian Health Regulatory Agency) and the Ministry of Health, and commercialization remains strictly regulated. The agency's decision regarding Embrapa (the Brazilian Agricultural Research Corporation) revives administrative precedents and technical votes that condition authorizations on individual projects and safety rules, showing that public policy has advanced through ad hoc decisions, without a single, consolidated framework.

In terms of access and production, Brazil has observed significant growth in the number of patients resorting to medicinal cannabis-based products, reflecting the increase in medical prescriptions, imports, and private supply, which puts pressure on solutions for national production, cost reduction, and…

11/20/2025 | Hora Campinas

https://horacampinas.com.br/estudo-aponta-maior-incidencia-de-doencas-cronicas-em-negros-no-brasil/ 

Director of the Campinas Institute of Clinical Research (IPEC) highlights the need to address fundamental social causes of inequality.

A recent, long-term study from the Longitudinal Study of Adult Health (Elsa-Brasil) reveals a disparity in the health of the Brazilian population. Rates of chronic diseases such as diabetes, hypertension, obesity, and chronic kidney disease are higher in the Black population (Black and mixed-race) compared to the white population in Brazil.

In an alert during Black Awareness Month, the Brazilian Society of Cardiology (SBC), through its Atherosclerosis Department, emphasizes that these diseases are risk factors for cardiovascular diseases, such as heart attack and stroke.

The Elsa-Brasil study, which followed 15,000 people in the country for 15 years, provided data justifying the urgency of the issue:

• Diabetes: 27.7% of the Black population has the disease, compared to 16% among whites.

• Hypertension (Overweight): 29.4% of the Black population is overweight, compared to 19.7% of the white population.

• Obesity: The obesity rate is 27.4% among Blacks, compared to 16.6% among whites.

• Chronic Kidney Disease: Affects 11.1% of the Black population and 7.9% of the white population.

Racism is a fundamental factor

For the Elsa-Brasil researchers, racism is recognized as one of the fundamental causes of these health inequalities. Cardiologist José Francisco Kerr Saraiva, director of the Campinas Clinical Research Institute (IPEC), reinforces this position.

“It is necessary to confront the fundamental social causes of inequality…